These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12967139)

  • 1. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ; Guerra ML; Kronish L
    Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
    Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
    Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
    J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
    Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
    Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
    Tester W; Ackler J; Tijani L; Leighton J
    Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
    Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
    Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
    Hahn NM; Marsh S; Fisher W; Langdon R; Zon R; Browning M; Johnson CS; Scott-Horton TJ; Li L; McLeod HL; Sweeney CJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6094-9. PubMed ID: 17062685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
    Mayordomo JI; Milla A; Morales S; Yubero A; Lorenzo A; Baena JM; Modolell A; Sanz J; Illarramendi J; Garcia MJ; Machengs I; Burrilo MA; Tres A
    Clin Breast Cancer; 2004 Jun; 5(2):131-5. PubMed ID: 15245617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
    Abratt RP; Brune D; Dimopoulos MA; Kliment J; Breza J; Selvaggi FP; Beuzeboc P; Demkow T; Oudard S
    Ann Oncol; 2004 Nov; 15(11):1613-21. PubMed ID: 15520061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
    Chittoor S; Berry W; Loesch D; Logie K; Fleagle J; Mull S; Boehm KA; Zhan F; Asmar L
    Clin Genitourin Cancer; 2006 Dec; 5(3):212-8. PubMed ID: 17239275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
    Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
    Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.
    Georgoulias V; Androulakis N; Bouros D; Kouroussis C; Chatzakis K; Papadakis M; Apostopoloulou F; Georgopoulou T; Kotsakis T; Souklakos J; Hatzidaki D; Vlachonikolis J; Panagos G
    Lung Cancer; 1998 Sep; 21(3):213-20. PubMed ID: 9857999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
    Sewak S; Chachoua A; Hamilton A; Taneja S; Lee J; Utate M; Sorich J; Muggia FM
    Anticancer Drugs; 2003 Jan; 14(1):67-72. PubMed ID: 12544260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.